RVMDRevolution Medicines, Inc.Running, no new patients
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic Cancer · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 500 (final count)
- Started
- Oct 16, 2024
- Main results expected
- Jun 2026
- Fully finished
- Dec 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression free survival (PFS) in the RAS G12-mutant population
Measured over: Up to approximately 3 years
Overall survival (OS) in the RAS G12-mutant population
Measured over: Up to approximately 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06625320 · record last updated 2026-06-02 · checked 2026-11-09 15:47 UTC